Zogenix acquires Modis Therapeutics and with it MT 1621 a treatment for Thymidine Kinase 2 deficiency

Zogenix, Inc. a global pharmaceutical company developing rare disease therapies, announced that it has entered into a definitive agreement to acquire Modis Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel therapies for rare genetic diseases with high unmet medical need. Modis’s lead product candidate, MT 1621, an investigational deoxynucleoside substrate enhancement therapy, is in late-stage development for the treatment of Thymidine Kinase 2 deficiency (TK2d), an inherited mitochondrial DNA depletion disorder that predominantly affects children and is often fatal.